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A b s T r A C T
background: patients with Cushing’s syndrome have a 
high prevalence of osteoporotic fractures. little is known 
about factors determining bone mineral density (bMd) in 
these patients.
objective: To evaluate which factors influence bMd at the 
time of diagnosis of Cushing’s syndrome.
Methods: in 77 consecutive patients with Cushing’s 
syndrome with a median age of 41.1 (interquartile range 31.1 
to 52.2) years we measured bMd of the lumbar spine and 
the femoral neck at the time of diagnosis. from the medical 
records we obtained information on possible predictors of 
bMd. we compared bMd with a reference population by 
means of the z score. Adjustment for other variables than 
age and sex was made with linear regression models.
results: patients with Cushing’s syndrome had a low z 
score in both the lumbar spine (–1.07 sd (95% Ci –1.43 
to –0.71 sd)) and in the femoral neck (–0.81 sd (95% Ci 
–1.06 to –0.55 sd)). 82% of patients had osteopenia at one 
or both sites (T score lower than –1 sd), including 31% with 
osteoporosis (T score –2.5 sd or lower).
The main determinant of the z score at both sites and for 
both sexes was age. z score increased by about 0.4 sd per 
decade. 81% of patients <40 years had osteopenia at one or 
both sites, including 31% with osteoporosis. for patients 
≥40 years these percentages were 83 and 32%, respectively. 
origin of Cushing’s syndrome, average 24-hour serum 
cortisol, duration of symptomatic glucocorticoid excess, 
sex, body mass index, menstrual status and duration of 
amenorrhoea did not influence the z score.
Conclusions: At the time of diagnosis, bMd in patients 
with Cushing’s syndrome is low compared with sex- and 
age-matched controls. The prevalence of osteopenia and 
osteoporosis at the time of diagnosis of Cushing’s syndrome 
is independent of age. Treatment with bisphosphonates 
should be considered in patients of all ages with Cushing’s 
syndrome who have a decreased bMd.
K E Y w o r d s
Cushing, endogenous glucocorticoid excess, bone mineral 
density, Z score, age, osteoporosis
i N T r o d u C T i o N
The association between hypercorticism and loss of skeletal 
mass was first described by Harvey Cushing.1 It is most 
likely that several factors act together in causing bone 
loss in Cushing’s syndrome. Glucocorticoids impair bone 
formation through direct effects on cells of osteoblastic 
lineage and they enhance bone resorption due to direct 
effects on osteoclasts.2,3 So, the coupling between bone 
resorption and bone formation, crucial to the normal 
process of bone remodelling, appears to be lost in active 
Cushing’s syndrome.4 Furthermore, there is a decrease 
in intestinal calcium absorption and in renal calcium 
reabsorption.5,6 Glucocorticoid-induced inhibition of 
gonadotropin and growth hormone secretion may also 
play a role, as well as glucocorticoid-induced decrease in 
muscular strength, leading to impaired physical activity.6,7
Bone loss due to treatment with pharmacological doses 
of glucocorticoids is more profound in trabecular than in 
cortical bone.5,8 This is supposedly related to the greater 
surface-to-volume ratio of trabecular bone compared with 
cortical bone. Since bone remodelling takes place at bone 
surfaces, trabecular bone responds more rapidly to either 
positive or negative changes in bone balance.9 In patients 
with endogenous hypercortisolism, bone loss in the lumbar 
spine, consisting mainly of trabecular bone, also seems 
to be more profound than bone loss in the femoral neck, 
consisting mainly of cortical bone.4,10-12
So far, little is known about factors that determine 
bone mineral density (BMD) in patients with untreated 
Cushing’s syndrome. The aim of the present study was 
to evaluate which factors influence BMD at the time of 
diagnosis of Cushing’s syndrome.
o r i g i N A l  A r T i C l E
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p A T i E N T s  A N d  M E T h o d s
Between 1989 and 2003, all patients newly diagnosed 
with Cushing’s syndrome referred to the Department 
of Endocrinology of the Radboud University Nijmegen 
Medical Centre in Nijmegen, the Netherlands underwent 
measurement of BMD of both the lumbar spine (L1-L4, 
posterior-anterior) and the right femoral neck. Before 
treatment of hypercortisolism, BMD was measured by 
dual-energy X-ray absorptiometry (DEXA, Hologic Inc., 
Waltham MA, before 1998 QDR-1000, thereafter QDR-
4500 Elite). The scanner was calibrated daily by means of 
phantom measurements. Vertebrae that showed artefacts 
due to fracture, spinal deformation and/or degenerative 
disease were excluded from the analysis. For each 
measured value of BMD (g/cm2) a T score and a Z score 
were calculated. A Z score of 0 SD means that the BMD is 
average for age and sex. From the medical records we also 
derived information on possible predictors of BMD.
To assess the effect of endogenous hypercortisolism 
on BMD we used the Z score, which implicitly means 
comparison with a reference group. To assess determinants 
of BMD within the group of Cushing patients we also 
used the Z score as measure of BMD, which means that 
comparisons are adjusted for age and sex. The comparisons 
were made by calculating mean differences in Z score 
between subgroups with corresponding 95% confidence 
intervals (95% CI). Adjustment for other variables than age 
and sex were made with linear regression models. To assess 
correlations between variables, we used Pearson correlation 
coefficients. To evaluate the risk for osteoporotic fractures 
we used the T score.
r E s u l T s
A total of 58 patients with untreated pituitary-dependent 
and 21 patients with untreated adrenal-dependent 
Cushing’s syndrome were seen during the study period. 
For unknown reasons, BMD measurements were not 
carried out in two patients with pituitary-dependent 
Cushing’s syndrome. Furthermore, we excluded patients 
with ectopic ACTH secretion from our analysis. Thus, 
BMD values of 56 patients with pituitary-dependent and 
21 patients with adrenal-dependent Cushing’s syndrome 
(15 adrenal adenoma, 4 adrenal carcinoma, and 2 bilateral 
macronodular hyperplasia) were available. The group 
consisted of 19 men and 58 women, median age 41.1 
(interquartile range 31.1 to 52.2) years. The average level 
of serum cortisol in blood samples taken over 24 hours 
at four hourly intervals was median 0.578 (interquartile 
range 0.498 to 0.668) mmol/l. Of the women, 21 were 
oligomenorrhoeic or eumenorrhoeic, whereas 31 women 
were postmenopausal or had been amenorrhoeic for at 
least six months secondary to the Cushing’s syndrome. 
Two patients had undergone extirpation of the uterus, and 
four women were on oral contraceptive agents. Median 
body mass index was 27.7 (interquartile range 25.2 to 32.5) 
kg/m2. The characteristics of patients of different ages, and 
patients with Cushing’s syndrome of different origins, did 
not differ with respect to the variables used in our analyses, 
except of course that older female patients were more often 
amenorrhoeic. None of the patients had previously taken 
drugs known to interfere with bone metabolism.
bMd at diagnosis of Cushing’s syndrome 
Before treatment, patients with Cushing’s syndrome had 
a low mean BMD. The decrease in BMD seemed to be 
more severe in the lumbar spine than in the femoral neck, 
although the difference was not statistically significant. In 
the lumbar spine we found a mean BMD of 0.89 g/cm2 
(95% CI 0.85 to 0.93 g/cm2), corresponding to a mean Z 
score of –1.07 SD (95% CI –1.43 to –0.71 SD), whereas in 
the femoral neck a mean BMD of 0.76 g/cm2 (95% CI 0.73 
to 0.79 g/cm2) was found with a mean Z score of –0.81 SD 
(95% CI –1.06 to –0.55 SD). In 73% of the patients, the Z 
score at one or both sites was lower than –1 SD, including 
16% who had a Z score of –2.5 SD or lower. A total of 82% 
had osteopenia at one or both sites, including 31% with 
osteoporosis according to World Health Organisation 
criteria. There was no significant difference in Z score 
between patients with Cushing’s syndrome of different 
origins. For patients with pituitary-dependent Cushing’s 
syndrome we found mean Z scores in the lumbar spine of 
–1.08 SD (95% CI –1.52 to –0.63 SD) and in the femoral 
neck of –0.66 SD (95% CI –0.99 to –0.33 SD), whereas 
for those with adrenal-dependent Cushing’s syndrome 
we found Z scores in the lumbar spine of –1.14 SD (95% 
CI –1.82 to -0.46 SD) and in the femoral neck of –1.14 SD 
(95% CI –1.55 to –0.74 SD).
factors predictive of bMd
Table 1 shows the relative influence of various variables on 
the Z score at the time of diagnosis of Cushing’s syndrome. 
Variables related to Cushing’s syndrome, such as origin 
of Cushing’s syndrome, average 24-hour serum level of 
cortisol and duration of symptomatic glucocorticoid excess, 
did not exert an influence on Z scores. In females, BMD of 
the femoral neck was lower than in males. When correcting 
for the other variables analysed, femoral neck BMD in 
females was 0.13 g/cm2 (95% CI 0.05 to 0.21) lower than 
in males. Interestingly, in males as well as in females, age 
correlated positively with Z score at both the lumbar spine 
and the femoral neck. Z scores increased by about 0.4 SD 
per decade (figure 1). Of female patients <40 years, 82% 
had a T score lower than –1 SD at one or both sites and 
27% had a T score of -2.5 SD or lower. For female patients 
≥40 years these percentages were 86 and 31%, respectively. 
Percentages for male patients were comparable. Of male 
patients under the age of 40 years, 79% had a T score lower 
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than –1 SD at one or both sites including the 36% who had 
a T score of -2.5 SD or lower. For male patients ≥40 years 
these percentages were 60 and 40%, respectively.
d i s C u s s i o N
The main finding of the present study is that in male as 
well as in female patients with Cushing’s syndrome, age 
correlated positively with Z scores, both in the lumbar spine 
and in the femoral neck. In Cushing patients of either sex 
the prevalence of osteopenia as well as of osteoporosis at 
either the lumbar spine or the femoral neck or at both sites 
was the same in patients <40 years compared with patients 
of ≥40 years. This explains why also young patients with 
Cushing’s syndrome have a considerable fracture risk.
We found that in patients with newly diagnosed endogenous 
Cushing’s syndrome, the mean Z score is approximately 1 SD 
below control values, consistent with previous reports.4,11,13-17 
The decrease in BMD seems to be more severe in the lumbar 
spine than in the femoral neck; however, as in previous 
reports10,11 the difference was not statistically significant.
Our data do not show a significant difference in BMD 
between patients with adrenal-dependent and pituitary-
dependent Cushing’s syndrome, neither in the group 
as a whole, nor in male or female patients separately. 
This confirms the findings in a very recent study by 
Tauchmanovà et al.15 In contrast, Ohmori et al.18 did 
find a lower BMD in females with adrenal-dependent 
Cushing’s syndrome than in females with pituitary-
dependent Cushing’s syndrome, both in the lumbar spine 
and in the femoral neck. In their study body mass index 
was significantly higher in patients with a pituitary origin 
of the disease than in those with an adrenal origin, which 
may explain their findings. Minetto et al.16 also found that 
lumbar spine BMD, but not femoral neck BMD, was lower 
in patients with adrenal-dependent than in patients with 
pituitary-dependent Cushing’s syndrome. 
In our study severity of Cushing’s syndrome, expressed as 
average 24-hour cortisol levels in serum, and duration of 
symptomatic glucocorticoid excess, did not influence Z scores. 
These findings are in line with observations in patients 
treated with pharmacological doses of glucocorticoids. In 
patients treated with glucocorticoids the daily dose does 
not correlate with BMD,19 and bone loss occurs particularly 
during the first months of treatment.19,20 At diagnosis of 
Cushing’s syndrome, the duration of glucocorticoid excess 
is usually more than a year, so it is not surprising that we did 
not observe a correlation between duration of symptomatic 
glucocorticoid excess and BMD. In our group of patients 
neither body mass index nor menstrual status showed a 
relation with Z scores. This is in line with observations 
published in a very recent report,15 but is in contrast with the 
situation in healthy subjects, where body mass index and 
menstrual status strongly influence BMD.21
The calculation of Z scores for BMD as measured by the 
two types of DEXA scanners used in our study was based 
on the same reference population, i.e. NHANES reference 
Table 1. Influence of variables on Z score (SD) of the lumbar spine (L1-L4) and the femoral neck at the time of 
diagnosis of Cushing’s syndrome
lumbar spine linear regression coefficient  
univariate (95% Ci)
linear regression coefficient 
multivariatea (95% Ci)
Origin of Cushing’s syndrome (adrenal versus pituitary) -0.08 (-0.85 to 0.70) 0.25 (-0.96 to 1.45)
Average 24h serum cortisol (mmol/l)b -1.61 (-3.89 to 0.67) -0.62 (-3.27 to 2.04)
Age (years) 0.04 (0.02 to 0.06)** 0.04 (0.003 to 0.07)*
Sex (male vs. female) -0.69 (-1.47 to 0.09) -0.34 (-1.52 to 0.84)
Body mass index (kg/m2) 0.03 (-0.03 to 0.09) 0.01 (-0.05 to 0.08)
Secondary amenorrhoea vs oligo-/eumenorrhoeac 0.17 (-0.55 to 0.88) 0.58 (-0.50 to 1.66)
Length of period of secondary amenorrhoea before DEXA  
measurement (years)c
0.04 (-0.02 to 0.11) 0.10 (-0.12 to 0.33)
femoral neck linear regression coefficient  
univariate (95% Ci)
linear regression coefficient 
multivariatea (95% Ci)
Origin of Cushing’s syndrome (adrenal vs. pituitary) -0.47 (-1.03 to 0.09) 0.14 (-0.64 to 0.92)
Average 24h serum cortisol (mmol/l)b 0.35 (-1.29 to 1.99) 1.32 (-0.37 to 3.01)
Age (years) 0.03 (0.01 to 0.05)** 0.04 (0.02 to 0.06)**
Sex (male vs. female) 0.47 (-0.12 to 1.06) 0.70 (-0.08 to 1.47)
Body mass index (kg/m2) 0.00 (-0.05 to 0.04) 0.00 (-0.05 to 0.04)
Secondary amenorrhoea vs oligo-/eumenorrhoeac 0.32 (-0.26 to 0.91) -0.41 (-1.39 to 0.57)
Length of period of secondary amenorrhoea before DEXA  
measurement (years)c
0.01 (-0.04 to 0.06) 0.03 (-0.14 to 0.21)
*p<0.05; **p<0.01. a Adjusted for age, sex, body mass index, origin of Cushing’s syndrome, and average 24-hour serum cortisol; bAverage 
of serum cortisol in blood samples taken at 0.00 h, 4.00 h, 8.00 h, 12.00 h, 16.00 h, and 20.00 h; csecondary amenorrhoea is defined as 
postmenopausal or amenorrhoeic for at least 6 months secondary to Cushing’s syndrome.
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population. Besides presenting Z-scores, for the purpose of 
clinical interpretation we pooled BMD values obtained by 
two types of DEXA scanners. This pooling is justified by the 
results of a study in which Litaker et al. compared repeatedly 
measured values of BMD within 219 individuals, as obtained 
by Hologic QDR-1000/W and 4500W DXA scanners. The 
difference between the mean values as measured by the two 
types of machines was only 0.02 g/cm2 in white females 
and 0.05 g/cm2 in white males. The differences found by 
Litaker et al. clearly pose a problem for the interpretation 
of longitudinal follow-up studies, measuring the gradual 
effect of the course of disease or cure within individuals. 
For cross-sectional studies, in contrast, describing a point 
estimate for the large effect of a situation such as the presence 
of Cushing’s syndrome, the disagreement between the 
machines is negligible. Indeed, the difference between the 
machines is far smaller than the difference we found between 
white, mostly female, patients with Cushing’s syndrome 
and the NHANES reference population (i.e. a decrease of 
1.07 SD ≈ 0.11 g/cm2 in lumbar spine and a decrease of 
0.81 SD ≈ 0.08 g/cm2 in femoral neck).22
The low R2 values we found using multivariate regression 
(0.145 for lumbar spine and 0.315 for femoral neck) 
indicate that there is a lot of variation in BMD that cannot 
be explained by the variables we used for our analyses. 
Therefore, one or more as yet undetermined (e.g. genetic) 
factors exert a strong influence on BMD in Cushing 
patients.
Osteoporosis is a well-known side effect of treatment 
with glucocorticoids. For patients in whom prednisone 
treatment is started with an intended treatment duration 
of at least three months at a dose of ≥7.5 mg per day, it is 
advised to add bisphosphonates.23 Although results in one 
nonrandomised study on alendronate therapy in patients 
treated for Cushing’s disease are promising,12 at present 
there is no consensus that patients with endogenous 
Cushing’s syndrome should start on bisphosphonates as 
soon as hypercortisolism has been demonstrated. One 
of the reasons for not giving bisphosphonates is the fact 
that BMD after cure of Cushing’s syndrome recovers 
spontaneously.4,11,13 However, normalisation of BMD in 
Cushing’s syndrome may last approximately ten years 
and it is not certain whether complete recovery occurs in 
every patient. At the time of diagnosis, 82% of our patients 
had a T score lower than –1 SD, and 31% had a T score 
of –2.5 SD or lower, consistent with a previous report.17 
figure 1: Influence of age on Z score of the lumbar spine (L1-L4; A and C) and the femoral neck (B and D) at the 
time of diagnosis of Cushing’s syndrome in both sexes
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Other authors found even higher prevalences.12,18 As a T 
score lower than –1 SD is associated with a 1.5- to 2-fold 
increase of the risk of fractures and a T score of –2.5 SD 
or lower is associated with a 3.5- to 4.5-fold increase of 
fracture risk in eucorticoid postmenopausal persons,24,25 
Cushing patients have a considerable fracture risk. 
Moreover, at comparable levels of BMD, patients treated 
with glucocorticoids have a higher risk of fractures 
than nonusers, probably reflecting glucocorticoid-
induced deterioration of bone quality.15,19,26-28 Indeed, 
the prevalence of osteoporotic fractures in patients with 
endogenous Cushing’s syndrome (30 to 76%) is higher 
than expected on the basis of BMD alone, particularly at 
the vertebral level.15,16,29-31
In summary, 82% of patients with untreated Cushing’s 
syndrome had a T score lower than –1 SD, including the 
31% of patients who had a T score of –2.5 SD or lower. 
Surprisingly, we found that the prevalence of osteopenia 
and osteoporosis at the time of diagnosis of Cushing’s 
syndrome was independent of age. As recovery of bone 
loss after treatment of Cushing’s syndrome may last 
many years, treatment with bisphosphonates should be 
considered in patients with Cushing’s syndrome who have 
a decreased BMD, independent of age. A randomised trial 
with sufficient power and duration of follow-up is needed 
to definitively prove that treatment with bisphosphonates 
accelerates the recovery of bone loss after successful 
treatment of Cushing’s syndrome and that treatment with 
bisphosphonates prevents fractures in patients with this 
disorder.
The data in this article were presented as a poster at Annual 
Meeting of the Endocrine Society 2006, in Boston, USA
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